DECKTHERAPEUTIC

decktherapeutic-logo

DeckTherapeutics specializes in acute omega-3 fatty acid therapeutics for neuroprotection. DeckTherapeutics' leadership team has expertise in omega-3 chemistry and biology, as well as drug and business development.

#People #Website #More

DECKTHERAPEUTIC

Social Links:

Industry:
Biotechnology Chemical Therapeutics

Address:
New York, New York, United States

Country:
United States

Website Url:
http://www.decktherapeutics.com

Status:
Active

Email Addresses:
[email protected]


Current Employees Featured

søren-weis-dahl_image

Søren Weis Dahl
Søren Weis Dahl Chief Executive Officer @ DeckTherapeutic
Chief Executive Officer
2020-12-01

Official Site Inspections

http://www.decktherapeutics.com

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "DeckTherapeutic"

Company - DeckTherapeutics

DeckTherapeutics is pioneering the new field of “acute omega-3 fatty acid therapeutics”. Emulsions of our proprietary semi-synthetic omega-3 compounds are administered …See details»

DeckTherapeutic - Crunchbase Company Profile & Funding

Organization. DeckTherapeutic . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. DeckTherapeutics specializes in …See details»

DeckTherapeutics, Inc. - LinkedIn

DeckTherapeutics, Inc. Biotechnology Research New York, New York 83 followers Pioneering neuroprotection using acute IV omega-3 therapeuticsSee details»

Contact Us - DeckTherapeutics

Acute Omega-3 Fatty Acids; Cell Death Pathways; Hypoxic-Ischemic Encephalopathy; Ischemia-reperfusion injuries; PublicationsSee details»

DeckTherapeutics - Devex

DeckTherapeutics’ leadership team brings together decades of experience and world-class science in the areas of omega-3 chemistry and biology and in drug and business …See details»

DeckTherapeutics - PitchBook

DeckTherapeutics General Information Description. Developer of omega-3 therapeutics intended to prevent paralysis and death after stroke. The company develops treatments for stroke and other acute organ injuries, enabling …See details»

DeckTherapeutics, Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for DeckTherapeutics, Inc. of Hastings On Hudson, NY. Get the latest business insights from Dun …See details»

DeckTherapeutics Inc. - VentureRadar

DeckTherapeutics is pioneering the new field of “acute omega-3 fatty acid therapeutics”. Emulsions of our proprietary semi-synthetic omega-3 compounds are administered …See details»

Deck Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials

Jul 15, 2023 New York, United States | www.decktherapeutics.com www.decktherapeutics.com. Last update 15 Jul 2023See details»

Decktherapeutics Company Profile | Management and Employees …

Find contact information for Decktherapeutics. Learn about their Research & Development, Business Services market share, competitors, and Decktherapeutics's email format.See details»

Decktherapeutics - Overview, News & Similar companies - ZoomInfo

Who is Decktherapeutics. DeckTherapeutics is pioneering acute IV injection of omega-3 diglycerides as safe and uniquely effective first-in-class therapeutics for the preven tion of …See details»

DeckTherapeutics - Products, Competitors, Financials, Employees ...

DeckTherapeutics focuses on the development of intravenous omega-3 fatty acid therapeutics for the treatment of acute hypoxic-ischemic injuries. The company's main product, THDG3, is a …See details»

Technology - DeckTherapeutics

We are pioneering neuroprotection using acute omega-3 fatty acid therapeutics developed by DeckTherapeutics’ Founder Dr. Richard Deckelbaum at Columbia University in New York, NY. …See details»

Dan Deckelbaum - DeckTherapeutics

Dan Deckelbaum, MD CHAIR OF THE BOARD OF DIRECTORS. Dan Deckelbaum MD CM, MPH, FRCS(C), is the co-director and founder of the Centre for Global Surgery and a critical …See details»

DeckTherapeutics - Company Profile - Tracxn

DeckTherapeutics - Developer of drug for traumatic brain injury. from 1 investor. DeckTherapeutics has 56 competitors.See details»

Charles H. Hood Foundation | DeckTherapeutics

Charles H. Hood Foundation | DeckTherapeutics By identifying innovative pediatric advancements and providing funding in the critical phases of development, we are able to expedite high …See details»

Imagining the future: A standard, emergency treatment for stroke

E: [email protected] Suman has more than 8 years of experience in basic and translational research (personalized medicine, stem cells, and pharmacogenetics) and 5 years …See details»

News - DeckTherapeutics

Dec 11, 2020 DeckTherapeutics awarded research grant for studies of THDG3 in higher animals. October 21, 2021. Dr. Rebecca Juliano joins DeckTherapeutics as Clinical Advisor. …See details»

DeckTherapeutics’ technology platform featured in The Wall Street ...

Sep 5, 2022 Founder of DeckTherapeutics, Columbia University Professor, Dr. Richard Deckelbaum, discusses the technology he and co-workers invented for intravenous (acute) …See details»